Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.

ABSTRACT:

Background

In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain and relapse. We conducted a cost-utility analysis of lurasidone versus aripiprazole from the perspective of healthcare services, using Scotland and Wales as specific case studies.

Methods

A 10-year Markov model, incorporating a 6-week acute phase and a maintenance phase across three health states (discontinuation, relapse, death) was constructed. Six-week probabilities of discontinuation and adverse events were based on a published independent mixed-treatment comparison; long-term

SUBMITTER: Rajagopalan K 

PROVIDER: S-EPMC4901121 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature